Skip to content

Impact of Preoperative Oral Carbohydrate Loading on Insulin Resistance in Adult Cardiac Surgery Patients

The Effect of Preoperative Oral Carbohydrate Loading on Insulin Resistance in Adult Patients Undergoing Cardiac Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07212153
Enrollment
50
Registered
2025-10-08
Start date
2024-01-01
Completion date
2024-05-30
Last updated
2025-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery, Insulin Resistance

Keywords

carbohydrate loading, insulin resistance, cardiac surgery, HOMA-IR

Brief summary

The goal of this clinical trial is to investigate the effect of preoperative oral carbohydrate on insulin resistance in adult cardiac surgery patients with a cardiopulmonary bypass machine. Insulin resistance is when the body does not respond well to insulin, which can raise blood sugar and slow recovery. The main question this study aims to answer is: Does drinking a carbohydrate drink 2 hours before surgery lower insulin resistance compared to drinking only water after on pump cardiac surgery? Researchers will compare two groups: One group will drink 400 milliliters of a maltodextrin (carbohydrate) drink (CL group). The other group will drink 400 milliliters of water (PL group). Participants will: 1. Be randomly assigned to one of the two groups. 2. Have blood samples taken to measure insulin and glucose before and after surgery (at hour-0, and hour-24 after ICU admission). 3. Be monitored in the intensive care unit for 24 hours after surgery.

Detailed description

This prospective, randomized controlled trial is designed to evaluate whether preoperative oral carbohydrate loading reduces perioperative insulin resistance in adults undergoing elective cardiac surgery at Dr. Sardjito Hospital, Yogyakarta, Indonesia. Fifty participants aged 20-60 years with American Society of Anesthesiologists (ASA) physical status II-III will be randomly assigned to one of two groups: 1. Intervention group (Carbohydrate Loading, CL): participants will receive 400 milliliters of a maltodextrin-based carbohydrate drink 2 hours before anesthesia. 2. Control group (Placebo Loading, PL): participants will receive 400 milliliters of plain water 2 hours before anesthesia. All participants will follow standard preoperative fasting guidelines. Blood samples for glucose and insulin will be taken immediately after induction of anesthesia, upon ICU admission (hour 0), and at hour 24 in the ICU. The main outcome is the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Secondary outcomes include perioperative glucose levels and postoperative insulin requirements. Randomization is computer-generated, with allocation concealed until assignment. Surgeons, anesthesiologists, ICU staff, outcome assessors, and data analysts will be blinded to group allocation. The sample size of 50 participants (25 per group) was calculated based on prior effect sizes, with 80% power and a two-sided alpha of 0.05. Data will be analyzed using descriptive statistics and appropriate tests for continuous and categorical variables. Between-group comparisons will use Student's t-test or Mann-Whitney U test as appropriate. Normality will be assessed by Shapiro-Wilk test. Repeated measures will be analyzed with paired tests or ANCOVA models. A p-value \<0.05 will be considered statistically significant. This study is expected to provide new evidence on whether preoperative carbohydrate loading can reduce insulin resistance in the specific context of cardiac surgery, and potentially improve perioperative management and patient recovery.

Interventions

DIETARY_SUPPLEMENTOral Carbohydrate Drink (Maltodextrin)

Participants receive 400 mL of a clear beverage containing 50 g of maltodextrin (carbohydrate) 2 hours before anesthesia induction. The drink is used to lower insulin resistance and improve perioperative recovery.

Participants receive 400 mL of plain water 2 hours before anesthesia induction, following the same protocol and timing as the carbohydrate drink group.

Sponsors

Rifdhani Fakhrudin Nur
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

This study is double-blind. Participants, care providers (surgeons, anesthesiologists, ICU staff), investigators, outcome assessors, data collectors, and analysts were blinded to group allocation. Only the designated study staff who handled randomization and intervention preparation had access to allocation information.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 20 to 60 years * ASA physical status II or III * Good tolerance to enteral fluid administration

Exclusion criteria

* History of diabetes mellitus * Thyroid insufficiency * Adrenal insufficiency * Gastroesophageal reflux disease * Emergency cardiac surgery Dropout criteria: * Participant withdraws consent * Cardiac surgery duration exceeds 4 hours

Design outcomes

Primary

MeasureTime frameDescription
HOMA-IR (Homeostasis Model Assessment for Insulin Resistance)baseline, 0 hour ICU admission, and 24 hours ICU admissionThe Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is calculated as fasting insulin (µU/mL) × fasting glucose (mmol/L) / 22.5. Higher values indicate greater insulin resistance.

Secondary

MeasureTime frameDescription
Perioperative Blood Glucose Levelsbaseline, 0 hour ICU admission, and 24 hours ICU admissionBlood glucose measured from central venous samples to assess changes in glucose metabolism during and after cardiac surgery.
Perioperative Serum Insulin Concentrationbaseline, 0 hour ICU admission, and 24 hours ICU admissionSerum insulin level measured from central venous blood samples to characterize perioperative insulin changes. Higher values indicate higher circulating insulin.

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026